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Abstract 
2-Amino-3-benzoylthiophenes suchas PD 81,273 (PD) have been shown to increase agonist, but not antagonist, radioligand binding 
and to enhance functional effects of A s adenosine receptor (A1AR) activation in tissues derived from rats and guinea-pigs. The 
mechanism by which PD produces this allosteric enhancement, a d its effect on human A1ARs was not known. In this study, we 
demonstrate hat PD modifies recombinant human A1AR binding and function in stably transfected CHO cells. In membranes, PD (20 
/.~M) causes: (i) a 3-fold increase in the fraction of receptors found in a high affinity G-protein coupled conformation as assessed by the 
binding of [12SI]N6-.(3-iodo-4-aminobenzyladenosine) (125I-ABA), an A1AR agonist; (ii) a 2.44-fold increase in the potency of the 
agonist R-N6-phenylisopropyladenosine (R-PIA) to compete for binding with the antagonist radioligand, [3H]8-cyclopentyl-l,3-dipro- 
pylxanthine ([3H]CPX); (iii) a 1.5-fold increase in the q/2 of 125I-ABA to dissociate from A1AR; and (iv) a 2.2-fold increase.in the 
concentration of guanosine-5'-3-O-(thio)triphosphate (GTPyS) required to half-maximally uncouple receptor-G-protein complexes. In 
intact CHO cells expressing A~AR, PD increases the potency of R-PIA to decrease forskolin-stimulated cAMP accumulation by 3.3-fold. 
We speculate that PD binds to A1AR at a site distinct from the agonist binding site and stabilizes agonist-R-G complexes. 
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1. Introduction 
Adenosine is known to affect a variety of tissues includ- 
ing cardiovascular, renal, gastrointestinal, immune and ner- 
vous [1]. The effects of adenosine are mediated by binding 
of adenosine to plasma membrane associated, G-protein 
coupled receptors [2]. The widely distributed adenosine 
receptors are sub-classified as A1, A2a , A2b and A3, based 
on molecular cloning, pharmacological and functional 
characteristics [3]. 
A series of 2-amino-3-benzoylthiophenes i cluding PD, 
Abbreviations: PD, 2-amino-4,5-dimethyl-3-thienyl-[3(trifluoro- 
methyl)-phenyl]methanone (PD81,723); All, adenosine receptor; 1251- 
ABA, [12SI]N6-[3-iodo-4-aminobenzyl)adenosine; CHA, N6-cyclohe - 
xyladenosine; CPA, N6-cyclopentyl-adenosine; CPX, 8-cyclopentyl-l,3- 
dipropylxanthine; DMSO, dimethyl sulfoxide; G-protein, guanine nu- 
cleotide binding protein; GTPyS, guanosine 5'-O-(3-thio)triphosphate; 
Hepes, N-[2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid]; NEM, 
N-ethylmaleimide; R-PIA, R-phenylisopropyladenosine. 
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have been found at concentrations < 20 /xM to increase 
agonist radioligand binding and functional activation of 
A IAR in rat brain and heart, guinea-pig heart and cultured 
FRTL-5 rat thyroid cells [4-8]. At higher concentrations, 
PD decreases the binding of agonists and antagonists to 
A1AR [4]. The action of this 'allosteric enhancer' is highly 
selective for A~AR [4,6]. PD has no effect on ligand 
binding to A2aAR present in the rat striatum, or to &opiate, 
M2-muscarinic, or oz2-adrenergic receptors [4]. The mecha- 
nism by which PD produces this allosteric enhancement, 
and its effect on human AaARs has been unknown. 
In the present study, we describe for the first time the 
effects of PD on the binding characteristics and function of 
recombinant human A IAR and determine the effects of 
PD on A IAR coupling to G-proteins. A number of com- 
pounds have been shown to act as allosteric enhancers or 
inhibitors for various receptors. These include gallamine 
with muscarinic receptors, benzodiazepines with GABA 
receptors, and amiloride with atrial natriuretic receptors 
[9-11]. The data suggest hat PD acts by a novel mecha- 
nism to stabilize agonist-AaAR-G-protein complexes. 
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2. Materials and methods 
2.1. Materials 
Hepes, Tris, NEM, MgC12, GTPyS, and forskolin were 
purchased from Sigma Chemical Co. (St. Louis, MO); 
R-PIA and CPX from Research Biochemicals; denosine 
deaminase from Boehringer Mannheim (Germany); DMSO 
from Fisher Scientific (NJ); and [3H]CPX (110 Ci/mmol) 
from DuPont NEN (Boston, MA). LY202472 (PD 81,723) 
and human A1AR stably transfected in CHO dhFr - cells 
(ATCC CRL 9096), were gifts from Robert Bruns (Ely 
Lilly, IN) and Marlene Jacobson (Merck Research, West 
Point, PA), respectively. 125I-ABA was synthesized as 
described [12]. Tissue culture reagents were from Gibco 
(Grand Island, NY). 
2.2. Cell culture 
CHO cells stably expressing human A1AR were grown 
to confluence on 150 mm plates (Falcon) in Iscove's 
medium (Gibco-BRL) supplemented with 10% fetal bovine 
serum, 100 U/ml  penicillin, 0.1 mg/ml streptomycin, 1 
mg/ml  G-418 (Gibco-BRL) and HAT (0.1 mM sodium 
hypoxanthine, 0.4 mM aminopterin, and 0.016 mM thymi- 
dine), in an atmosphere of 95% air/5% CO 2 at 37°C. 
Cells were seeded at 0.2-1 × 104 cells/cm 2 and subcul- 
tured after detaching with trypsin/EDTA (0.05%; 0.5 
mM). 
2.3. Membrane preparations 
CHO cells expressing human AIAR were harvested 
from culture dishes in 30 ml of buffer A [10 mM Hepes, 
10 mM EDTA, 0.1 mM benzamidine (pH 7.4) at 4°C] 
using a rubber policeman and homogenized using a 
Brinkmann tissue disrupter at setting 5 for 20 s. The 
homogenate was centrifuged at 40000 X g for 20 min. 
Pellets were resuspended in 30 ml of ice-cold HE [10 mM 
Hepes, 1 mM EDTA and 0.1 mM benzamidine (pH 7.4)] 
and recentrifuged. The process was repeated and the final 
membrane pellet resuspended in HE supplemented with 
10% w/v  sucrose and stored in aliquots (1 mg membrane 
protein/ml) at -20°C. Protein was measured by fluo- 
rescamine fluorescence using bovine serum albumin stan- 
dards [13]. 
2.4. Radioligand binding 
For equilibrium binding assays, 0.01-0.1 mg membrane 
protein was incubated with adenosine deaminase (1 U/ml) 
in HE with radioligand (125I-ABA or [3H]CPX) and in 
some cases competing ligands, for 3 h at 21°C in a volume 
of 100 /zl. The bound and free radioligand was separated 
by filtration through Whatman GF/C  filter paper using a 
Brandel tissue harvester. Binding assays were performed in 
triplicate and nonspecific binding determined by adding 1 
/~M CPX either prior to or at the same time as radioligand. 
At their respective Ka, nonspecific radioligand binding is 
13% and 3% of total binding. To measure dissociation 
kinetics, 125I-ABA was bound to equilibrium and then 20 
/xM R-PIA was added alone or in combination with PD 
for various times prior to filtration. In some instances the 
dissociation rate was accelerated by raising the incubation 
temperature to 37°C. 
2.5. Cyclic AMP assays 
cAMP determinations were made on cells in suspension 
following their removal from plates by treatment with 5 
mM EDTA in PBS for 5-10 min. Cells were washed twice 
with PBS and resuspended at room temperature in serum 
free DMEM supplemented with 20 mM Hepes (pH 7.4), 
containing 10 U/ml  adenosine deaminase nd pipetted 
into test tubes (50000 to 70000 cells/0.2 ml, 21°C). 
Drugs were added in 50 ~1 aliquots and the tubes trans- 
ferred to a 37°C shaker bath for 10 min. Assays were 
terminated by the addition of 500 /~1 of 0.15 N HC1. 
Following centrifugation at 2000 × g for 15 min to pellet 
cellular debris, cAMP in the acid extract (500 /zl) was 
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Fig. 1. Effects of PD on the binding of radioligands to A1AR. The effect of different concentrations of PD on the binding of the agonist, 12SI-ABA, 0.3 nM 
(left), and the antagonist, [3H]CPX, 0.5 nM (right). Radioligands and membranes i olated from CHO cell expressing A~AR were equilibrated for 3 h at 
21°C. Data are means + S.E. of specific binding pooled from three independent experiments, each assayed in triplicate. 
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Fig. 2. Effect of PD (20 /xM) on the equilibrium binding of 125I-ABA to membranes of CHO cells expressing AJAR. Equilibrium-specific binding (left) 
and Scatchard-transformed (right) binding isotherms are shown. Data are means + S.E. of specific binding pooled from three independent experiments, 
each assayed in triplicate. Binding parameters are summarized in the text. 
acetylated by addition of 22.5 /xl of triethylamine/acetic 
anhydride (3.5:1 v /v )  and quantified by automated ra- 
dioimmunoassay. 
2.6. Data analysis 
Binding parameters (Kd, B . . . .  Ki ,  ICs0) were fit by 
Marquart's nonlinear least squares interpolation to equa- 
tions for one or multiple binding sites, as described previ- 
ously [14]. Dissociation rates were fit to a 2-component 
exponential binding model. 
3. Results 
3.1. Concentration-dependent effects of PD on radioligand 
binding to human A1AR 
We first determined the effect of PD on the binding of 
radioligands to recombinant human A1AR. Fig. 1 shows a 
typical concentration response curves of PD on membranes 
isolated from CHO cells stably expressing human A~AR 
using fixed concentrations of radioligands (added at half 
their Kas). The curve obtained for the agonist, 125I-ABA, 
is biphasic. PD increases pecific 125I-ABA binding by 
about 100% at 20 /xM (maximal effect) and the enhance- 
ment decreases at higher concentrations. When the same 
experiment is performed using the antagonist, [3H]CPX, as 
the radioligand, PD does not enhance but only inhibits 
binding at higher concentrations. The K i of PD as an 
antagonist is 39 /xM. These data are similar to previous 
results with rat brain membranes [4] where PD enhances 
agonist binding at lower concentrations but reduces antag- 
onist binding at higher concentrations. We used 20 /xM 
PD as the optimum concentration to maximize PD en- 
hancement in subsequent experiments. 
3.2. Effect of PD (20 tzM) on 125I-ABA and [3H]CPX 
binding 
The effect of 20 /xM PD on the concentration depen- 
dence of a25I-ABA binding measured at equilibrium is 
illustrated in Fig. 2. Agonist binding was performed in the 
absence of any added Mg 2+ because in preliminary exper- 
iments (data not shown) PD was found to affect binding 
maximally in the absence of divalent cations. Equilibrium 
binding parameters (Bma x and K~) were best fit to a two 
site binding model. In three experiments PD was found to 
significantly increase the Bma x of the high affinity binding 
site from control, 598 _+ 108 fmol/mg protein, to 1669 _-t- 
415 fmol/mg protein. Although the high affinity K d was 
not significantly affected (0.59 _+ 0.19 vs. 0.86 + 0.30 nM), 
it is possible that low levels of adenosine present in 
membranes might mask changes in the affinity, particu- 
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Fig. 3. Effect of PD (20 /xM) on the 3 equilibrium binding of [ H]CPX to membranes of CHO cells expressing A1AR. Equilibrium-specific binding (left) 
and Scatchard-transformed (right) binding isotherms are shown. Data from a single experiment assayed in triplicate are shown. Similar results were 
obtained in two additional experiments. Binding parameters are summarized in the text. 
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Fig. 4. Effect of PD (20 /xM) on competition by R-PIA for [3H]CPX 
binding to A1AR. Competition data are pooled from six independent 
experiments. Binding is plotted as a fraction of control specific binding. 
Refer to the text for ICs0 values. Hill coefficients are 0.92 + 0.058 and 
0.87 + 0.061 in absence and presence of PD, respectively. 
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Fig. 5. Effect of NEM on the enhancement of 125I-ABA binding to A1AR 
by PD. CHO cell membranes were preincubated with 100 /xM NEM 
prior to the addition of radioligand and PD. Data are the means __ S.E. of 
specific binding pooled from three experiments, each assayed in tripli- 
cate. 
larly to high affinity sites, since the binding of both the 
radioligand and residual adenosine would be affected. 
The affinity of 125I-ABA for low affinity binding sites 
could not be determined accurately. To learn more about 
the effects of PD, we used [3H]CPX to determine the total 
number of receptors (coupled and uncoupled), and the 
affinity of R-PIA in competition assays. As shown in Fig. 
3, the total number of A 1 receptors measured with [ 3 H]CPX 
binding is 15 180 + 640 and 13 590 + 860 fmol/mg pro- 
tein, in the absence and presence of 20 /xM PD, respec- 
tively. Thus, by comparing the number of high affinity 
125I-ABA binding sites to the number of [3H]CPX binding 
sites we calculate that recombinant A~ adenosine recep- 
tors, measured in the absence of Mg 2+, are 4% and 12% 
coupled in the absence and presence of 20 /xM PD, 
respectively. In competition binding assays (Fig. 4), the 
IC50 of R-PIA is left shifted by an average of 2.44-fold, 
from an ICs0 of 4.0_+1.15 to 1.55_+0.48 /xM (n=6,  
P < 0.01 by paired analysis). Since [3H]CPX labels pri- 
marily uncoupled receptors, these data suggest hat PD 
may increase the affinity of uncoupled A 1 adenosine re- 
ceptors for agonists. 
To investigate this further, receptor-G-protein com- 
plexes were uncoupled by inactivating the oz-subunits of 
G-proteins with NEM (15). The effect of PD (20 /xM) on 
the specific binding of 125I-ABA in the presence and 
absence of 100 /zM NEM is shown in Fig. 5. After 
treatment with this uncoupling agent, PD (20-50 /xM) 
produces a 1.4-1.5-fold increase in specific binding at- 
tributable to the action of PD to increase lzSI-ABA binding 
affinity. A substantially larger increase in binding noted in 
the absence of NEM can be attributed to the ability of PD 
to increase receptor G-protein coupling, as mentioned 
above. 
Fig. 6 (left) shows the effect of PD on the dissociation 
rate of 125I-ABA in Mg2+-free buffer. Dissociation occurs 
in two kinetically distinct components. The first compo- 
nent, probably reflecting low affinity binding, is too rapid 
to be measured accurately by the filtration assays used in
this series of experiments. In three experiments, 20 /xM 
PD increased the tl/2 of the slow, high affinity component 
by 1.52-fold from 18 _+ 2.8 to 27.3 _+ 3.3 min (P < 0.05 by 
paired analysis). The fact that PD apparently fails to 
increase the affinity of 125I-ABA for high affinity binding 
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Fig. 6. Effect of PD on the dissociation kinetics of 125I-ABA from A1AR. Membranes derived from CHO cells transfected with AIAR were incubated 
with 125I-ABA (0.5 nM) for 1 h at 37°C in the absence (left) or presence (right) of 2.5 mM MgC12. R-PIA (20 /zM) with or without PD (20 /zM) was 
added for various times prior to filtration. Specific binding is normalized to binding at equilibrium. The data were fit to a bi-exponential decay model and 
are typical of five experiments, three assayed in the absence, and two in the presence of MgC12 in which PD consistently decreased by > 1.6-fold the slow 
component of ]25I-ABA dissociation. 
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Fig. 7. Effect of PD and GTPTS on 125I-ABA binding to A1AR. 
Membranes from CHO cells transfected with A1AR were incubated at
21°C with 0.5 nM 125I-ABA and various concentrations f GTPyS, as 
indicated. Each point is the mean+S.E, of data pooled from th ee 
experiments, each assayed in triplicate. 
sites in equilibrium binding assays (Fig. 2) seems to be at 
odds with the finding that PD significantly decreases the 
high affinity dissociation rate. We hypothesized that en- 
dogenous adenosine might have interfered with equilib- 
rium but not kinetic assays. By this logic, we hypothesized 
that PD would decrease the dissociation rate of ~25I-ABA 
in the presence of Mg 2+, even though there is little effect 
of PD on 125I-ABA binding in the presence of the divalent 
cation. This proved to be correct. In two experiments with 
MgC12 added, 20 /zM PD decreased the dissociation rate 
constant, by 3.0- and 5.2-fold (Fig. 6, right). 
presence of PD (20 /zM) by 2.2-fold to 0.344 __+ 0.017/xM 
(P < 0.01 by paired analysis, n = 3). 
3.4. Functional enhancement of human A 1AR by PD 
Activation of A~AR decreases adenylyl cyclase activ- 
ity. The effects of PD on A1AR mediated inhibition of 
forskolin-stimulated cAMP accumulation was charac- 
terized with the AIAR agonist R-PIA in transfected CHO 
cells. R-PIA decreased cAMP accumulation by 50% at 0.1 
nM (Fig. 8). This very high potency, and the large number 
of [3H]CPX binding sites, suggests that there may be spare 
recombinant receptors. PD causes a leftward shift in the 
concentration response curve to R-PIA and produces a 
30% inhibition of cAMP accumulation i the absence of 
added agonist. The effect of PD alone was observed 
despite the addition of 10 U/ml  adenosine deaminase to 
the cells to deaminate endogenous adenosine. The effect of 
PD to inhibit cAMP accumulation i the absence of added 
agonist is blocked by 30 nM CPX, a competitive A1AR 
antagonist. Thus, in the presence of 30 nM CPX, the effect 
of PD alone to decrease cyclic AMP levels is abolished 
(Fig. 8). R-PIA can overcome the competitive blockade by 
CPX, and 20 /xM PD shifts the R-PIA concentration 
response curve measured in the presence of CPX 3.3-fold 
from an IC50 of 5.3 _ 0.26 nM to 1.6 _ 0.26 nM (P < 0.01; 
n = 3). The fact that PD shifts the potency, but not the 
efficacy of R-PIA is consistent with the possible existence 
of spare recombinant A~ adenosine receptors on these 
cells. 
3.3. Effect of PD on the sensitivity of agonist binding to 
guanine nucleotides 4. Discussion 
The ability of nonhydrolyzable analogs of GTP such as 
GTPyS to decrease agonist binding can be used to measure 
the effect of guanine nucleotides on receptor-G-protein 
coupling [16-18]. The concentration response curve of 
GTPTS to inhibit 125I-ABA binding to A1AR is shifted to 
the right in presence of PD as illustrated in Fig. 7. The 
EDs0 of GTPyS, 0.16 + 0.016 /xM, is increased in the 
Several studies uggest that activation of A1AR present 
in heart and brain protects hese organs against hypoxic 
and ischemic damage [19-21]. 2-Amino-3-benzoyl- 
thiophenes such as PD are of interest both because of the 
potential clinical benefit of enhancing the activity of A 1AR 
selectively in ischemic areas, and because of the unusual 
mechanism of action of this class of compounds. We 
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Fig. 8. Effects of PD on cyclic AMP accumulation n CHO cells transfected with ALAN. Cells were incubated without (left) or with PD (20 /xM) (right) 
for 10 min with 10 U/ml adenosine d aminase, 30nM CPX (where indicated) and various concentrations f R-PIA and 5 /xM forskolin. Data are 
expressed aspercent of forskolin- stimulated cAMP concentration (mean + S.E., n = 3). 
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report here for the first time, activity by PD on human 
AIAR and some new information about molecular mecha- 
nisms underlying its action. 
PD increases agonist binding to human A1AR by in- 
creasing binding affinity and by enhancing coupling of 
receptors to G-proteins. This is manifested by an increase 
in the fraction of receptors found in a high affinity state, 
and a decrease in dissociation rate of an agonist radioli- 
gand, 125I-ABA, in kinetic assays. Unexpectedly, PD failed 
to increase the binding affinity of 125I-ABA, to high 
affinity sites as measured in equilibrium binding assays. 
PD also had very little affect on high affinity equilibrium 
agonist binding in the presence of Mg 2+, which promotes 
R-G coupling. Our recent data, however, suggests that it 
is very difficult to completely deplete membranes of en- 
dogenous adenosine [22]. The effect of PD on high affinity 
agonist radioligand binding may therefore be masked by 
low levels of residual adenosine that competes for radioli- 
gand binding. Such residual adenosine would not interfere 
with dissociation kinetics, since the rate of dissociation of 
the radioligand should not be influenced by partial receptor 
occupancy by adenosine. In support of this idea is the 
finding that the addition of Mg 2+ does not prevent PD 
from reducing the dissociation rate for 12SI-ABA. It is 
notable also that PD is effective in intact cells, where 
Mg 2÷ is present. We conclude that the difficulty in seeing 
an effect of the enhancer on high affinity agonist binding 
in equilibrium assays may be due to competition for 
binding by endogenous adenosine. Endogenous adenosine 
may also contribute to the apparent inhibitory effect of PD 
on antagonist radioligand binding by enhancing the po- 
tency of the competing nucleoside. Nevertheless, the 
biphasic effect of PD on 125I-ABA binding is consistent 
with the notion proposed previously that the enhancing and 
the antagonist activities of PD are due to two distinct 
binding sites on the A 1 adenosine receptor [4]. 
PD increased the potency of R-PIA to compete for 
[3H]CPX binding to membranes and it increased binding 
of 125I-ABA to receptors uncoupled with NEM [15]. These 
data suggest that PD can act directly to increase the 
affinity of agonists, to receptors uncoupled from G-pro- 
teins. 
A novel and interesting finding of this study is that PD 
shifts the concentration response curve of GTPyS to the 
right, thereby decreasing the potency of GTPTS to lower 
agonist affinity by 2.2-fold. This may be a manifestation f
a stabilizing effect of PD on the conformation of the 
ligand-receptor-G-protein r ary complex that binds ago- 
nists with high affinity. In this conformational state the 
G-protein is free of guanine nucleotide, so it is reasonable 
to expect hat stabilization f this complex by PD could 
result in a drop in the affinity of the G-protein for guanine 
nucleotide. In intact cells, where guanine nucleotide levels 
are high, this effect will presumably not significantly 
reduce G-protein activation, although it is possible to 
imagine a situation in broken cells assayed with low levels 
of GTP or GTPTS, in which PD may reduce G-protein 
activation. 
Consistent with its effects on agonist binding is the 
finding that PD enhances inhibition of cyclic AMP produc- 
tion by the adenosine analog, R-PIA, in intact CHO cells 
transfected with the A1AR. PD also enhances cyclic AMP 
accumulation i  the absence of any added agonist. The 
latter effect may result because PD augments the action of 
a low level of adenosine present in cells that is not 
removed by the addition of adenosine deaminase, or PD 
enhances constitutive receptor activity. Consistent with 
these possibilities i  the finding that CPX blocks this effect 
of the enhancer seen in the absence of an added agonist. 
CPX, could act as an antagonist of endogenous adenosine 
or as an inverse agonist o counteract onstitutive receptor 
activity. A small degree of intrinsic activity by unliganded 
receptors could take on increased significance in recombi- 
nant as opposed to wild-type systems due to expression of 
very large numbers of receptors. 
The effect of PD appears to involve a change in the 
interaction between the AIAR and G-protein. It remains to 
be determined if these two proteins alone are sufficient for 
enhancer activity, and if PD has differential effects on 
receptors coupled to different G proteins. 
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